by Savitha C Muppala on  April 1, 2011 at 8:07 PM Drug News
 Motesanib Does Not Make a Mark in NSCLC Study
Motesanib, a drug meant for those cancers which are difficult to treat , has unfortunately not lived up to expectations in the phase III trial.

Infact, it did not make any significant contribution in improving the survival rate among victims of non-small cell lung cancer (NSCLC).


Nearly 1,090 patients with advanced nonsquamous NSCLC were part of the study.



Source: Medindia

Most Popular on Medindia